<SEC-DOCUMENT>0001193125-25-200830.txt : 20250911
<SEC-HEADER>0001193125-25-200830.hdr.sgml : 20250911
<ACCEPTANCE-DATETIME>20250911092302
ACCESSION NUMBER:		0001193125-25-200830
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250911
DATE AS OF CHANGE:		20250911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284606
		FILM NUMBER:		251307349

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d803649d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-284606</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2025) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>274,666 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>137,333,300 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g803649g0911073027884.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2025 (the
&#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-284606),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on September&nbsp;11, 2025 (the &#8220;September 11, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#8221;).</FONT> Accordingly, we have
attached the September&nbsp;11, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;KZIA.&#8221; On September&nbsp;10, 2025, the last reported
sale price of the ADSs on Nasdaq was $8.25 per ADS. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 9 of the Prospectus and the &#8220;Risk
Factors&#8221; in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other
recently filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is September&nbsp;11, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;11, 2025, Kazia Therapeutics Limited (the &#8220;Company&#8221;) issued a press release titled &#8220;Kazia
Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy.&#8221; A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote
of Dr.&nbsp;John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#8217;s registration statement on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-3&nbsp;(File&nbsp;No.&nbsp;333-281937).</FONT></FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated September&nbsp;11, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: September&nbsp;11, 2025</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib
Monotherapy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, Australia &#8211; September&nbsp;11, 2025 &#8211; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development
company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this ex vivo study, blood
samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia&#8217;s investigational PI3K&#8211;mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a
statistically significant reduction in single circulating tumor cells and achieved a complete (100%) disruption of circulating tumor cell (CTC) clusters containing three or more cells.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HER2-positive breast cancer accounts for 15&#8211;20% of cases and remains a clinical challenge despite the
transformative impact of HER2-targeted therapies, with many patients experiencing resistance, recurrence, or metastasis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immunotherapy has demonstrated success across several solid tumors but has shown limited efficacy in
HER2-positive breast cancer, underscoring the need for new therapeutic approaches. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In this study, liquid biopsy profiling of Stage IV patients revealed that paxalisib treatment effectively
disrupted CTCs and CTC clusters, which are considered biomarkers of aggressive disease and metastasis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immunofluorescence analyses showed that paxalisib-treated blood samples from HER2-positive mBC patients achieved
complete disruption of highly metastatic CTC clusters (&#8805;3 cells). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;This monotherapy
<FONT STYLE="white-space:nowrap">ex-vivo</FONT> result extends our understanding of paxalisib&#8217;s potential beyond triple-negative breast cancer into HER2-positive disease,&#8221; said Dr.&nbsp;John Friend, CEO of Kazia Therapeutics. &#8220;The
ability to disrupt circulating tumor cell clusters, which are strongly associated with metastasis and poor prognosis, represents a transformative therapeutic avenue. We are particularly excited by the precision medicine aspect of this work, which
leverages biomarkers to both track metastatic burden and guide therapeutic decisions. This work underscores Kazia&#8217;s commitment to expanding paxalisib&#8217;s utility across multiple subtypes of advanced breast cancer, addressing high unmet
need in patients with limited options.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These findings complement Kazia&#8217;s ongoing Phase 1b trial in Stage IV triple-negative breast cancer
(TNBC), where initial patient data announced in July 2025 demonstrated significant reductions in circulating tumor cells and clusters, underscoring the broader potential of paxalisib to address metastatic progression across multiple breast cancer
subtypes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detailed datasets encompassing
metastatic signatures and disrupted progenitor populations in Stage IV HER2-positive breast cancer have been submitted for presentation at an upcoming global oncology meeting in 2025. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC,
Astarr@lifesciadvisors.com, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat
multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported
in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline
gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma
by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric
Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule
inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been
completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;future,&#8221; &#8220;forward,&#8221; &#8220;anticipate,&#8221; or other similar
words. Any statement describing Kazia&#8217;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to,
statements regarding: the timing for results and data related to Kazia&#8217;s clinical and preclinical trials, including the potential presentation at an oncology conference of comprehensive datasets, including analyses of metastatic signatures and
disrupted progenitor populations in Stage IV HER2-positive breast cancer patients, Kazia&#8217;s strategy and plans with respect to its paxalisib program, the potential results of its Phase 1b clinical trial evaluating paxalisib in combination with
olaparib or pembrolizumab for patients with advanced breast cancer, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market
opportunity for paxalisib. Such statements are based on Kazia&#8217;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not
be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia&#8217;s ability to regain and/or maintain compliance with the applicable Nasdaq continued
listing requirements and standards. These and other risks and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
uncertainties are described more fully in Kazia&#8217;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States
Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place
undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by
Dr John Friend, CEO </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g803649g0911073027884.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g803649g0911073027884.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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MW.?TH2NP;L>C49KP";XA^,+;'GR&+=]WS(=N:[_X<ZOKFOVUU?ZK,K0;A'
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GQ7M%E2UC6<AI0H#$=":M4GW1Q2U):5D+1244#%HI** %HI** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
